Context Therapeutics Inc. - Common Stock (CNTX)
CUSIP: 21077P108
Q4 2023 13F Holders as of 31 Dec 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 91,741,639
- Total 13F shares
- 3,558,639
- Share change
- +979,983
- Total reported value
- $4,020,714
- Price per share
- $1.13
- Number of holders
- 24
- Value change
- +$1,102,318
- Number of buys
- 9
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21077P108:
Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.79%
|
725,951
|
$1,096,186 | — | 30 Sep 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.65%
|
593,491
|
$896,171 | — | 30 Sep 2023 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.36%
|
328,817
|
$496,514 | — | 30 Sep 2023 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.32%
|
295,700
|
$446,507 | — | 30 Sep 2023 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.14%
|
125,852
|
$190,000 | — | 30 Sep 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
105,809
|
$159,772 | — | 30 Sep 2023 | |
| Mill Creek Capital Advisors, LLC |
13F
|
Company |
0.11%
|
104,631
|
$157,993 | — | 30 Sep 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
97,240
|
$146,908 | — | 30 Sep 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
37,219
|
$56,201 | — | 30 Sep 2023 | |
| Clear Harbor Asset Management, LLC |
13F
|
Company |
0.04%
|
36,000
|
$54,360 | — | 30 Sep 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
32,907
|
$49,690 | — | 30 Sep 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
30,100
|
$45,000 | — | 30 Sep 2023 | |
| SHEETS SMITH WEALTH MANAGEMENT |
13F
|
Company |
0.02%
|
20,000
|
$30,200 | — | 30 Sep 2023 | |
| XTX Topco Ltd |
13F
|
Company |
0.01%
|
13,259
|
$20,021 | — | 30 Sep 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.01%
|
10,438
|
$15,761 | — | 30 Sep 2023 | |
| Aspire Wealth Management Corp |
13F
|
Company |
0.01%
|
10,000
|
$15,100 | — | 30 Sep 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
8,963
|
$13,534 | — | 30 Sep 2023 | |
| Tarek Sahmoud |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$8,415 | — | 16 Aug 2022 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,500
|
$2,265 | — | 30 Sep 2023 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
400
|
$604 | — | 30 Sep 2023 | |
| Retirement Group, LLC |
13F
|
Company |
0%
|
155
|
$234 | — | 30 Sep 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
108
|
$163 | — | 30 Sep 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
100
|
$151 | — | 30 Sep 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
16
|
$24 | — | 30 Sep 2023 | |
| Evan G. Dick |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
29,223
|
— | — | 15 Feb 2022 | |
| William F. Rencher |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
8,000
|
— | — | 15 Feb 2022 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q4 2023
As of 31 Dec 2023,
Context Therapeutics Inc. - Common Stock (CNTX) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,558,639 shares.
The largest 10 holders included
Opaleye Management Inc., Ally Bridge Group (NY) LLC, VANGUARD GROUP INC, Affinity Asset Advisors, LLC, UBS OCONNOR LLC, HighTower Advisors, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Mill Creek Capital Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, and NORTHERN TRUST CORP.
This page lists
24
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
23
Q4 2023 holders
24
Holder diff
1
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 Value $ | Q4 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.